Table 1.
Demographic, clinical, and laboratory characteristics of the study population.
| Patients’ Characteristics | COVID-19 Group N: 67 |
Control Group N: 67 |
p |
|---|---|---|---|
| Males, n (%) | 47 (70%) | 35 (52%) | 0.09 |
| Age <40 yy, n (%) | 2 (3%) | 3 (4%) | 0.67 |
| Age 40–60 yy, n (%) | 19 (28%) | 15 (22%) | 0.74 |
| Age >60 yy, n (%) | 46 (68%) | 49 (73%) | 0.09 |
| Cardiovascular diseases, n (%) | 28 (41%) | 25 (37%) | 0.99 |
| Concomitant Antiplatelets Drugs, n (%) | 22 (32%) | 30 (44%) | 0.06 |
| Concomitant Anticoagulants Drugs, n (%) | 6 (9%) | 10 (14%) | 0.12 |
| Asymptomatic Pneumonia, n (%) | 2 (3%) | 0 (0%) | 0.24 |
| Abnormal PT sec, n (%) | 16 (23%) | 7 (10%) | 0.09 |
| Abnormal aPTT, n (%) | 2 (3%) | 1 (2%) | 0.73 |
| D-dimer>500–700 mcg/dL, n (%) | 54 (80%) | 40 (59%) | 0.09 |
| Fibrinogen >400 mg/dL, n (%) | 58 (86%) | 39 (58%) | 0.005 |
COVID-19: coronavirus disease 2019; PT: prothrombin time; aPTT: activated thromboplastin time.